Island Pharmaceuticals Secures U.S. Patent for Galidesivir Against Filoviridae Viruses
Island Pharmaceuticals announced that the U.S. Patent and Trademark Office has granted U.S. Patent No. 12,508,266 for the use of its antiviral drug Galidesivir to treat infections caused by Filoviridae viruses, such as Marburg and Ebola, providing intellectual property protection through October 14, 2031. The patent strengthens Island’s expanding Galidesivir IP portfolio and aligns with the company’s clinical development strategy, which includes advancing the drug under the FDA’s Animal Rule pathway. 
Island Pharmaceuticals Secures U.S. Patent for Galidesivir Against Filoviridae Viruses